Centessa Pharmaceuticals plc (CNTA)
Automate Your Wheel Strategy on CNTA
With Tiblio's Option Bot, you can configure your own wheel strategy including CNTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CNTA
- Rev/Share 0.0
- Book/Share 2.9034
- PB 4.8909
- Debt/Equity 0.021
- CurrentRatio 14.3673
- ROIC -0.3953
- MktCap 1896475292.0
- FreeCF/Share -1.2181
- PFCF -11.7031
- PE -8.4384
- Debt/Assets 0.0154
- DivYield 0
- ROE -0.569
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CNTA | Needham | -- | Buy | -- | $35 | May 28, 2025 |
| Initiation | CNTA | Chardan Capital Markets | -- | Buy | -- | $30 | May 8, 2025 |
| Initiation | CNTA | Piper Sandler | -- | Overweight | -- | $38 | March 31, 2025 |
| Initiation | CNTA | TD Cowen | -- | Buy | -- | -- | Jan. 7, 2025 |
| Upgrade | CNTA | Morgan Stanley | Equal Weight | Overweight | $11 | $26 | Sept. 20, 2024 |
| Initiation | CNTA | B. Riley Securities | -- | Buy | -- | $33 | Sept. 19, 2024 |
News
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Centessa Pharmaceuticals (CNTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders. ORX142 is the second drug candidate from the Company's multi-asset orexin franchise.
Read More
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 138.8% upside potential for Centessa Pharmaceuticals (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Read More
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2024.
Read More
About Centessa Pharmaceuticals plc (CNTA)
- IPO Date 2021-05-28
- Website https://www.centessa.com
- Industry Biotechnology
- CEO Dr. Saurabh Saha M.D., Ph.D.
- Employees 77